Physician profile
Stewart Bae
NPI 1205910999
$6,703.45
in general payments reported to CMS, 2019-2025
41 companies · $830 in 2025
The $830 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,315 · 2020: $822 · 2021: $1,166 · 2022: $796 · 2023: $833 · 2024: $942 · 2025: $830.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,368 · Education: $237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,367.53 |
| Education | $237.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,210.36 | 2019-2025 | Farxiga, Lokelma |
| Novo Nordisk INC | $863.61 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amarin Pharma, INC. | $684.33 | 2019-2023 | |
| Amgen INC. | $553.65 | 2019-2025 | Repatha, Tavneos, Otezla |
| Opko Pharmaceuticals, LLC | $481.16 | 2019-2025 | Rayaldee |
| Lilly USA, LLC | $406.10 | 2019-2024 | Mounjaro |
| Vifor Pharma, INC. | $212.24 | 2019-2025 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $193.39 | 2021-2024 | |
| Xeris Pharmaceuticals, INC. | $181.83 | 2023-2025 | Gvoke Hypopen, Keveyis |
| Gilead Sciences, INC. | $165.70 | 2021-2022 | |
| Fresenius USA Marketing, INC. | $135.06 | 2019-2023 | Korsuva, Velphoro |
| Ani Pharmaceuticals, INC. | $134.71 | 2023-2025 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $120.88 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $115.29 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $104.68 | 2019-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stewart Bae listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.